Eton Pharmaceuticals (ETON) news
Recent news
Eton Pharmaceuticals - To pay aQuestive royalties at mid-teens percentage rate on Libervant sales - SEC filing
Eton Pharmaceuticals has agreed to pay Aquestive Therapeutics royalties at a mid-teens percentage rate on future sales of Libervant, according to a recent SEC filing. The details of the agreement were disclosed in a regulatory submission, which outlines the financial terms of the partnership .…
AInvest Wire · 23h agoEton Pharmaceuticals - To pay Aquestive up to $47.50 mln in milestone payments - SEC filing
Eton Pharmaceuticals has agreed to pay Aquestive Therapeutics, Inc. up to $47.5 million in milestone payments, according to a recent SEC filing . The terms of the agreement outline specific financial obligations tied to the achievement of development and regulatory milestones related to one of…
AInvest Wire · 23h agoEton Pharmaceuticals - Type 9 NDA under FDA review to add ages 6-11 to Libervant label; PDUFA date March 29, 2027
Eton Pharmaceuticals is currently seeking to expand the approved age range for its drug Libervant through a Type 9 New Drug Application (NDA) under review by the U.S. Food and Drug Administration (FDA). The company aims to add children aged 6 to 11 to the existing label for Libervant, which is…
AInvest Wire · 1d agoEton Pharmaceuticals - Libervant expected to be eligible for full approval in patients 12+ after Jan 10, 2027
AInvest Wire · 1d agoEton Pharma, Aquestive Thera enter exclusive license pact
AInvest Wire · 1d agoLight Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.